SUMMARY

• Abilify Asimtufii (aripiprazole) is an intramuscular gluteal injection administered by a healthcare professional once every 2-months for treatment of adults with schizophrenia and as maintenance monotherapy for adults with bipolar I disorder.¹
• There are currently no head-to-head studies examining the efficacy and safety of INVEGA SUSTENNA or INVEGA TRINZA compared to Abilify Asimtufii.^2,3

BACKGROUND

Abilify Asimtufii (960 mg and 720 mg) is administered once every 2-months in the gluteal muscle by a healthcare professional and is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.¹

For questions on this product, please refer to the manufacturer.

INVEGA SUSTENNA (39 mg, 78 mg, 117 mg, 156 mg, and 234 mg) is a 1-month intramuscular deltoid or gluteal injection administered by a healthcare professional. INVEGA SUSTENNA is indicated in adults for the treatment of schizophrenia and schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.²

INVEGA TRINZA (273 mg, 410 mg, 546 mg, or 819 mg) is a 3-month intramuscular deltoid or gluteal injection administered by a healthcare professional. INVEGA TRINZA is indicated for the treatment of schizophrenia in adults after they have been adequately treated with INVEGA SUSTENNA for at least four months.³

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, DERWENT^® (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 12 April 2024.